Leaderboards/histiocytic disorders and treatments

histiocytic disorders and treatments

Last updated June 11, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Aurélien Mattuizzi
Hôpital Pellegrin
99
2
Estibaliz Lazaro
Centre National de la Recherche Scientifique
90
3
Paul G. Kemps
Leiden University Medical Center
80
4
James A. Whitlock
University of Toronto
60

Rising Stars Papers

Insufficient data

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Alice A. Lee
Children's Hospital at Montefiore
99
2
Joshua Friedman
Icahn School of Medicine at Mount Sinai
90
3
Margaret E. Macy
Children's Hospital Colorado
80
4
Seerwan Hamadameen Sulaiman
Lebanese French University
70
5
D. Williams Parsons
Baylor College of Medicine
60
6
Mohammed Alsaeed
Riyadh Armed Forces Hospital
50
7
Jitka Rybová
Medical College of Wisconsin
50
8
JunYi Qiao
Sichuan University
30
9
Olga Lytvynova
Cleveland Clinic
20
10
S. Dhakal
National Academy of Medical Sciences
10

Emerging Leaders Papers

1
Circulating tumor DNA sequencing of pediatric solid and brain tumor patients: An institutional feasibility study
Pediatric Hematology and Oncology|2023
6 cit.
2
Hematopoietic stem cell transplantation leads to biochemical and functional correction in two mouse models of acid ceramidase deficiency
Molecular Therapy|2024
5 cit.

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Omar Abdel‐Wahab
Memorial Sloan Kettering Cancer Center
99
2
Richard D. Brunning
University of Minnesota
90
3
Jean‐François Emile
Assistance Publique – Hôpitaux de Paris
80
4
David M. Hyman
Memorial Sloan Kettering Cancer Center
70
5
Oussama Abla
University of Toronto
70
6
Yuchiao Chang
Harvard University
60
7
A. FLAISLER
Institut Gustave Roussy
50
8
C. Cameron Yin
The University of Texas MD Anderson Cancer Center
40
9
Andrés Tirado‐Sánchez
Mexican Social Security Institute
40
10
Jeffrey A. Medin
Medical College of Wisconsin
40

All-Time Leaders Papers

1
A view on drug resistance in cancer
Nature|2019
2.7k cit.
2
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
New England Journal of Medicine|2015
1.7k cit.
3
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
Blood|2016
1.5k cit.
4
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease
Blood|2018
614 cit.
5
Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman disease
Modern Pathology|2017
292 cit.
6
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
Nature Medicine|2019
226 cit.
7
Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression
Journal for ImmunoTherapy of Cancer|2020
36 cit.
8
Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation
Cancer Discovery|2022
36 cit.
9
Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia
Nature Cancer|2023
21 cit.
10
Hepatic pathology and altered gene transcription in a murine model of acid ceramidase deficiency
Laboratory Investigation|2019
15 cit.

Reagents for histiocytic disorders and treatments

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Recommended

Best all-around

Cell Signaling Technology

Phospho-p90RSK (Thr573) Antibody

#9346$148
View Evidence →Cell Signaling Technology

POMC (D3R1U) Rabbit Monoclonal Antibody

#23499$161
View Evidence →Cell Signaling Technology

Docetaxel

#9886$75
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

FXR2 (D85D6) Rabbit Monoclonal Antibody

Cited in 5 papers
#7098$161
View Evidence →Cell Signaling Technology

FYVE-CENT Antibody

Cited in 5 papers
#8532$317
View Evidence →Cell Signaling Technology

DDX5 (D15E10) Rabbit Monoclonal Antibody

#9877$159
View Evidence →